Omnicell stockholders approve equity plan amendment

Omnicell , Inc. (NASDAQ:OMCL), a healthcare technology company with a market capitalization of $1.32 billion, announced on Friday that its stockholders have approved an amendment to its 2009 Equity Incentive Plan. According to InvestingPro analysis, the company is currently trading below its Fair Value, while maintaining a moderate debt level with a debt-to-equity ratio of 0.31. The amendment, which was passed during the Annual Meeting of Stockholders on May 21, 2025, includes the addition of 1,750,000 shares of common stock authorized for issuance under the plan.

The approval came as part of the company’s annual meeting, where several key proposals were voted upon. The amendment to the Equity Incentive Plan was detailed in the company’s Proxy Statement filed on April 3, 2025, and the full text of the amended plan was attached as Appendix A to the Proxy Statement.

In addition to the plan amendment, the election of three Class III directors to hold office until the 2028 Annual Meeting of Stockholders was confirmed. Edward P. Bousa, Mary Garrett, and Bruce E. Scott will continue to serve on the company’s Board of Directors.

The advisory vote to approve named executive officer compensation was also passed, alongside the ratification of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the year ending December 31, 2025.

The results of the voting for the election of directors were as follows: Edward P. Bousa received 35,421,552 votes for and 2,264,612 withheld, with 4,279,972 broker non-votes. Mary Garrett received 34,722,222 votes for and 2,963,942 withheld, with 4,279,972 broker non-votes. Bruce E. Scott received 34,114,987 votes for and 3,571,177 withheld, with 4,279,972 broker non-votes.

The advisory vote on executive compensation saw 35,780,985 votes for, 1,724,508 against, and 180,671 abstentions, with 4,279,972 broker non-votes. The amendment to the 2009 Equity Incentive Plan was approved with 35,600,671 votes for, 1,915,066 against, and 170,427 abstentions, plus 4,279,972 broker non-votes.

The ratification of the independent registered public accounting firm was passed with 41,527,276 votes for, 166,260 against, and 272,600 abstentions.

This information is based on a press release statement and provides a factual account of Omnicell, Inc.’s recent stockholder meeting outcomes and the related 8-K filing. Looking ahead, InvestingPro forecasts indicate positive earnings expectations, with analysts projecting EPS of $1.20 for FY2025. For deeper insights into Omnicell’s financial health and detailed analysis, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.

In other recent news, Omnicell Inc. reported its first-quarter 2025 earnings, surpassing analyst expectations with an earnings per share (EPS) of $0.26, compared to the forecasted $0.21. Total (EPA:TTEF) revenue for the quarter reached $270 million, marking a $24 million increase from the previous year. Despite the positive earnings, Omnicell’s stock experienced a decline following the earnings release, reflecting investor concerns over broader financial and operational updates. Additionally, Omnicell has updated its full-year 2025 guidance, raising the lower end of its adjusted EPS and EBITDA estimates due to a more favorable outlook on China tariffs. The company also announced a $75 million share repurchase program. On the product front, Omnicell introduced the MedTrack RFID Line and MedVision software to improve medication management in healthcare settings. In terms of analyst activity, BofA Securities raised Omnicell’s stock price target from $30 to $34, maintaining a Neutral rating, while Benchmark lowered its target from $62 to $40, retaining a Buy rating. These developments highlight Omnicell’s efforts to navigate tariff challenges and its ongoing commitment to innovation in healthcare solutions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.